CIViC Evidence Items
4766 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| B | IGH::DUX4 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia With DUX4 Rearrangement | Zhang et al., 2016 | |
| B | IGH::DUX4 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia With DUX4 Rearrangement | Lilljebjörn et al., 2016 | |
| B | IGH::DUX4 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia With DUX4 Rearrangement | Gu et al., 2019 | |
| B | v::IRF4 | Fusion | Diagnostic | Supports | Positive | Large B-cell Lymphoma With IRF4 Rearrangement | Salaverria et al., 2011 | |
| B | v::IRF4 | Fusion | Diagnostic | Supports | Positive | Large B-cell Lymphoma With IRF4 Rearrangement | Ramis-Zaldivar et al., 2020 | |
| B | v::JAK2 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like | Roberts et al., 2012 | |
| D | AR | AR-V7 | Oncogenic | Supports | Oncogenicity | Prostate Cancer | Guo et al., 2009 | |
| D | AR | AR-V7 | Oncogenic | Supports | Oncogenicity | Prostate Cancer | Hu et al., 2009 | |
| B | RBM15::MRTFA | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With T(1;22)(p13;q13) | Ma et al., 2001 | |
| B | RBM15::MRTFA | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With T(1;22)(p13;q13) | de Rooij et al., 2017 | |
| B | RBM15::MRTFA | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With T(1;22)(p13;q13) | Inaba et al., 2015 | |
| A | KRAS | G12C | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Panitumumab,Sotorasib | Fakih et al., 2023 |
| C | PML::RARA | Fusion | Diagnostic | Supports | Positive | Acute Promyelocytic Leukemia With PML-RARA | Santana-Hernández et al., 2024 | |
| C | PML::RARA | Fusion | Diagnostic | Supports | Positive | Acute Promyelocytic Leukemia With PML-RARA | Ismail et al., 2007 | |
| C | PML::RARA | Fusion | Diagnostic | Supports | Positive | Acute Promyelocytic Leukemia With PML-RARA | Iaccarino et al., 2019 | |
| B | ETV6::RUNX1 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma With ETV6-RUNX1 | Borkhardt et al., 1997 | |
| B | FUS::ERG | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukaemia With FUS::ERG Fusion | Kong et al., 1997 | |
| B | FUS::ERG | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukaemia With FUS::ERG Fusion | Noort et al., 2018 | |
| C | v::TFCP2 | Fusion | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Agaram et al., 2019 | |
| C | FUS::TFCP2 | Fusion | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Dashti et al., 2018 | |
| C | SMARCB1 | LOSS OF NUCLEAR PROTEIN EXPRESSION | Diagnostic | Supports | Positive | Cribriform Neuroepithelial Tumor | Johann et al., 2017 | |
| B | PML::RARA | Fusion | Diagnostic | Supports | Positive | Acute Promyelocytic Leukemia With PML-RARA | de Thé et al., 1990 | |
| B | PML::RARA | Fusion | Diagnostic | Supports | Positive | Acute Promyelocytic Leukemia With PML-RARA | Longo et al., 1990 | |
| C | EGFR::RAD51 | e24::e4 | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Erlotinib | Zhu et al., 2018 |
| B | ETV6::RUNX1 | Fusion | Predictive | Supports | Adverse Response | B-lymphoblastic Leukemia/lymphoma With ETV6-RUNX1 | Not Applicable | Romana et al., 1995 |
| B | ETV6::RUNX1 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma With ETV6-RUNX1 | Shurtleff et al., 1995 | |
| B | NUP98::v | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With NUP98 Rearrangement | de Rooij et al., 2016 | |
| B | NUP98::v | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With NUP98 Rearrangement | Hollink et al., 2011 | |
| B | NUP98::v | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With NUP98 Rearrangement | Ostronoff et al., 2014 | |
| B | NUP98::v | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With NUP98 Rearrangement | Bertrums et al., 2023 | |
| C | IGH::EPOR | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like | Long et al., 2024 | |
| C | IGH::EPOR | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like | Liu et al., 2020 | |
| B | IGH::EPOR | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like | Jaso et al., 2014 | |
| C | IGH::EPOR | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like | Niswander et al., 2021 | |
| B | EPOR | rearrangements | Diagnostic | Supports | Positive | B-lymphoblastic Leukemia/lymphoma, BCR-ABL1–like | Iacobucci et al., 2016 | |
| C | FUS::TFCP2 | Fusion AND ALK Exon 2-18 Deletion | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Csizmok et al., 2024 | |
| B | KMT2A::v | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With MLL Rearrangement | Bolouri et al., 2018 | |
| B | KMT2A::v | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With MLL Rearrangement | van Weelderen et al., 2024 | |
| B | KMT2A::v | Fusion | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With MLL Rearrangement | Meyer et al., 2023 | |
| B | COL1A1::PDGFB | Fusion | Diagnostic | Supports | Positive | Dermatofibrosarcoma Protuberans | Patel et al., 2008 | |
| B | COL1A1::PDGFB | Fusion | Diagnostic | Supports | Positive | Dermatofibrosarcoma Protuberans | Segura et al., 2011 | |
| D | FUS::DDIT3 | Fusion | Diagnostic | Supports | Positive | Myxoid Liposarcoma | Pérez-Losada et al., 2000 | |
| B | AR | AR-V7 | Predictive | Supports | Resistance | Prostate Cancer | Abiraterone,Enzalutamide | Scher et al., 2016 |
| B | AR | AR-V7 | Predictive | Supports | Resistance | Prostate Cancer | Abiraterone,Enzalutamide | Scher et al., 2018 |
| D | AR | AR-V7 | Oncogenic | Supports | Oncogenicity | Prostate Cancer | Han et al., 2024 | |
| B | v::ZNF384 | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukaemia/lymphoma With Other Defined Genetic Alterations | Hirabayashi et al., 2017 | |
| B | KMT2A::v | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukaemia/lymphoma With KMT2A Rearrangement | Meyer et al., 2018 | |
| B | KMT2A::v | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukaemia/lymphoma With KMT2A Rearrangement | Brady et al., 2022 | |
| B | KMT2A::v | Fusion | Diagnostic | Supports | Positive | B-lymphoblastic Leukaemia/lymphoma With KMT2A Rearrangement | Aypar et al., 2024 | |
| B | NPM1 | MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With Mutated NPM1 | Falini et al., 2005 |